Cellectar Biosciences Inc (CLRB)

[oddone33320]

Reverse Split was approved by shareholders during the shareholder meeting at the end of May this year. Will be interesting to see what management settles on and when they will implement.

I'm concerned that they are trying to uplist too soon. If they uplist this early in the game they will likely be manipulated and shorted which is rampant in big board stocks that are development stage.

If you are a long ways to product approval and have no other source of revenue except for private placements then this is a longgg ride up and down, up and down....UP briefly when it's time to raise money (or great early trial results are had), and DOWN when wall street wants to make money by shorting which is more predictable and easier for them to do....until the company has a drug approved and then it's up for a good while.